Hepatitis treatment update: new approvals, not much news. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Hepatitis treatment update: new approvals, not much news.

Notes Undergr. 1998-99 Winter;(No 38):7-8. Unique Identifier : AIDSLINE AIDS/20700059
Learned J

Abstract: Thymosin-Alpha-1 (Zadaxin) is a synthetic hormone that has been studied as a treatment for HIV, hepatitis B, and hepatitis C. Recently approved in Mexico as a booster for the flu vaccine, it was also approved in nine other countries for flu, hepatitis B, and hepatitis C. The demand for Thymosin is great but it is difficult to procure. A partnership between Schering-Plough and SciClone Pharmaceuticals has renewed hope that the demand for Thymosin will be met. Schering-Plough is also marketing Rebetron, a packaged combination of Ribavirin capsules and injectable alpha-interferon (Intron-A), for the treatment of hepatitis C. Other hepatitis treatments are described, such as Epivir-HBV (3TC, Epivir) which was approved in December for the treatment of Hepatitis B. Epivir-HBV has shown promising results.

Keywords: NEWSLETTER ARTICLE Antiviral Agents/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Drug Approval Drug Therapy, Combination Hepatitis B, Chronic/*DRUG THERAPY Hepatitis C, Chronic/*DRUG THERAPY Human Interferon Alfa-2b/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Lamivudine/*ADMINISTRATION & DOSAGE Mexico Plant Extracts/ADMINISTRATION & DOSAGE Ribavirin/*ADMINISTRATION & DOSAGE Thymosin/*ANALOGS & DERIVATIVES/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS

KWDnewsletterarticleantiviralagents/KWDadministration&dosage/adverseeffectsdrugapprovaldrugtherapy,combinationhepatitisb,chronic/KWDdrugtherapyhepatitisc,chronic/KWDdrugtherapyhumaninterferonalfa-2b/KWDadministration&dosage/adverseeffectslamivudine/KWDadministration&dosagemexicoplantextracts/administration&dosageribavirin/KWDadministration&dosagethymosin/KWDanalogs&derivatives/administration&dosage/adverseeffects
000330
A0030890

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .